2-1250 Waverley Street
Winnipeg, MB R3T 6C6
Canada
204 487 7412
https://www.medicure.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Neil Owens Ph.D. | President & COO | 149.37k | N/A | N/A |
Dr. Reuben Saba Ph.D. | Vice President of Scientific & Medical Affairs | 110.03k | N/A | N/A |
Dr. Albert David Friesen Ph.D. | Founder, CEO & Chairman of the board | 173.12k | N/A | 1947 |
Mr. Haaris Uddin B.Com., CPA | Chief Financial Officer | 44.17k | N/A | N/A |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Medicure Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.